Investorideas.com - Actively Traded Health and Biotech OTCBB Stocks; OTCVolumeLeaders.com ($0.50-$1.00): (AFLB, RMCP, SILA, KORE)
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) September 9, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.50-$1.00) include A5 LABORATORIES INC. (OTCBB: AFLB), Revolutions Medical Corporation (OTCBB: RMCP), Gold American Mining Corp. (OTCBB: SILA), and Kore Nutrition, Inc. (OTCBB: KORE).
Sign up for Tomorrows Hot OTC Market Leaders Today!http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
One of the OTCBB volume leader reports; Recent News; "Kore Nutrition Incorporated ("Kore" or the "Company") and the Company's wholly owned subsidiary, Go All In, Inc. ("ALL IN") are pleased to announce a new distribution agreement with PPNC Distributing Co. of Placentia, California ("PPNC"). ALL IN Energy products have been accepted for distribution to over 400 grocery stores in Southern California."
Full Article: http://finance.yahoo.com/news/ALL-IN-Energy-Completes-New-prnews-2018501746.html?x=0&.v=8
Market Snapshot: (at time of release)
Dow 10,451.68 +64.67 +0.62%
Nasdaq 2,246.30 +17.43 +0.78%
S&P 500 1,108.37 +9.50 +0.86%
10 Yr Bond(%) 2.7220% +0.6800
Oil 74.80 +0.13 +0.17%
Gold 1,254.10 -1.50 -0.12%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Thursday, September 9, 2010
Wednesday, September 8, 2010
Investorideas.com - Biotech/Pharma Stocks and Oil & Gas Stocks; Most Active OTCBB Stocks ($1.00-$2.00): (TGMP, NNVC, WGBS, ALME)
Investorideas.com - Biotech/Pharma Stocks and Oil & Gas Stocks; Most Active OTCBB Stocks ($1.00-$2.00): (TGMP, NNVC, WGBS, ALME)
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) September 8, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include American Power Corp. (OTCBB: TGMP), NanoViricides, Inc. (OTCBB: NNVC), WaferGen Biosystems, Inc. (OTCBB: WGBS), and Alamo Energy Corp. (OTCBB: ALME).
Sign up for Tomorrows Hot OTC Market Leaders Today!http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
One of the OTCBB volume leader reports; Recent News; "American Power Corp. ("American Power" or "the Company") is pleased to provide additional information on its Pace Coal Project in Judith Basin County, Montana.
Up until 1921, a subsidiary of the Great Northern Railway Co. mined in excess of 1.3 million tons of coal from the Lehigh mine located at the heart of American Power's Pace Coal Project. At that time, the mined coal was transported by railway to other parts of America. American Power now plans to carry out confirmatory exploration work with the goal of re-establishing production on the property, and deliver coal to power plants and/or coal gasification projects over the established railway network."
Full article: http://finance.yahoo.com/news/American-Power-Corp-Update-on-iw-3051908032.html?x=0&.v=1
(OTCBB: AQUM)
Market Snapshot: (at time of release)
Dow 10,372.63 +31.94 +0.31%
Nasdaq 2,223.79 +14.90 +0.67%
S&P 500 1,096.98 +5.14 +0.47%
10 Yr Bond(%) 2.6360% +0.2700
Oil 75.14 +1.05 +1.42%
Gold 1,257.00 -0.30 -0.02%
Sector Snapshot: (at time of release)
MACHINERY 2.9%INTERNET 2.1%STEEL/IRON 2%BANK 1.9%INSURANCE 1.8%SHIPPING 1.8%OIL DRILLER 1.6%SOLAR 1.6%AGRICULTURE 1.4%NETWORK 1.1%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/
Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/
OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) September 8, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include American Power Corp. (OTCBB: TGMP), NanoViricides, Inc. (OTCBB: NNVC), WaferGen Biosystems, Inc. (OTCBB: WGBS), and Alamo Energy Corp. (OTCBB: ALME).
Sign up for Tomorrows Hot OTC Market Leaders Today!http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
One of the OTCBB volume leader reports; Recent News; "American Power Corp. ("American Power" or "the Company") is pleased to provide additional information on its Pace Coal Project in Judith Basin County, Montana.
Up until 1921, a subsidiary of the Great Northern Railway Co. mined in excess of 1.3 million tons of coal from the Lehigh mine located at the heart of American Power's Pace Coal Project. At that time, the mined coal was transported by railway to other parts of America. American Power now plans to carry out confirmatory exploration work with the goal of re-establishing production on the property, and deliver coal to power plants and/or coal gasification projects over the established railway network."
Full article: http://finance.yahoo.com/news/American-Power-Corp-Update-on-iw-3051908032.html?x=0&.v=1
(OTCBB: AQUM)
Market Snapshot: (at time of release)
Dow 10,372.63 +31.94 +0.31%
Nasdaq 2,223.79 +14.90 +0.67%
S&P 500 1,096.98 +5.14 +0.47%
10 Yr Bond(%) 2.6360% +0.2700
Oil 75.14 +1.05 +1.42%
Gold 1,257.00 -0.30 -0.02%
Sector Snapshot: (at time of release)
MACHINERY 2.9%INTERNET 2.1%STEEL/IRON 2%BANK 1.9%INSURANCE 1.8%SHIPPING 1.8%OIL DRILLER 1.6%SOLAR 1.6%AGRICULTURE 1.4%NETWORK 1.1%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/
Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/
OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Tuesday, September 7, 2010
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX), Inc. to Present at the Rodman & Renshaw Healthcare Conference
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX), Inc. to Present at the Rodman & Renshaw Healthcare Conference
Visit this company: www.biosantepharma.com
LINCOLNSHIRE, Ill. - September 7, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Rodman & Renshaw Healthcare Conference being held in the New York Palace Hotel, New York City from September 12-15, 2010.
Stephen M. Simes, BioSante's president & chief executive officer, will speak on Tuesday, September 14 at 9:10 am ET. Mr. Simes will provide a status update on BioSante's lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante. A live audio webcast of Mr. Simes' remarks may be accessed at http://www.wsw.com/webcast/rrshq18/bpax and a replay will be available at the same link.
On the same day at 1 pm ET, Mr. Simes will participate on a panel titled: Structural Changes in the Capital Markets and Their Impact on Emerging Life Science Companies.
About the Rodman Healthcare Conference
The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.
Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Contact:
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com Request News and Info on BPAX Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Visit this company: www.biosantepharma.com
LINCOLNSHIRE, Ill. - September 7, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Rodman & Renshaw Healthcare Conference being held in the New York Palace Hotel, New York City from September 12-15, 2010.
Stephen M. Simes, BioSante's president & chief executive officer, will speak on Tuesday, September 14 at 9:10 am ET. Mr. Simes will provide a status update on BioSante's lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante. A live audio webcast of Mr. Simes' remarks may be accessed at http://www.wsw.com/webcast/rrshq18/bpax and a replay will be available at the same link.
On the same day at 1 pm ET, Mr. Simes will participate on a panel titled: Structural Changes in the Capital Markets and Their Impact on Emerging Life Science Companies.
About the Rodman Healthcare Conference
The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.
Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Contact:
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com Request News and Info on BPAX Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Thursday, September 2, 2010
Investorideas.com - Healthcare Software Development Company, HealthMed Services (OTCBB: HEME) Announces it will Acquire Rights to Neural Communicator
Investorideas.com - Healthcare Software Development Company, HealthMed Services (OTCBB: HEME) Announces it will Acquire Rights to Neural Communicator
Neural Communicator’s brain/computer interface devices and software enable patients with extreme disabilities to communicate
Visit this company: www.healthmedltd.com
Thursday September 2, 2010 - (Investorideas.com Newswire) Software development company, HealthMed Services Ltd. (OTCBB:HEME), reports it has entered final negotiations to acquire all rights, title and interest to Neural Communicator software and hardware.
Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. The device detects eye movement, jaw contractions and ALPHA and BETA brain waves allowing hands free input.
Neural Communicator is intended for people disabled in such a way that they cannot communicate by speech or by using their body. Biofeedback is used for computer input and controlling the application features.
The software is based on plug-in architecture allowing easy implementation of new features. There are five basic modules:
Speech module - text input for speech replacement; GSM module - send and receive SMS; MSN module; Windows Live Messenger chat Book Reader - reading books by speech synthesis; and Web Browsing - special plug-ins for Bing Maps and Facebook.
The developers of the software and hardware will continue to work with HealthMed on an outsourcing basis in developing further applications for the Neural Communicator.
President/CFO John Popovic commented, "We are extremely keen on completing the acquisition of Neural Communicator. The product will bring easy communication capability to those currently unable to communicate as well as expanding the communication ability of others with disabilities restricting their communication capacity. Acquiring this leading edge technology expands HealthMed's product lineup and will position us strongly in the marketplace."
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact: John Popovic
www.healthmedltd.com866.428.5689
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Neural Communicator’s brain/computer interface devices and software enable patients with extreme disabilities to communicate
Visit this company: www.healthmedltd.com
Thursday September 2, 2010 - (Investorideas.com Newswire) Software development company, HealthMed Services Ltd. (OTCBB:HEME), reports it has entered final negotiations to acquire all rights, title and interest to Neural Communicator software and hardware.
Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. The device detects eye movement, jaw contractions and ALPHA and BETA brain waves allowing hands free input.
Neural Communicator is intended for people disabled in such a way that they cannot communicate by speech or by using their body. Biofeedback is used for computer input and controlling the application features.
The software is based on plug-in architecture allowing easy implementation of new features. There are five basic modules:
Speech module - text input for speech replacement; GSM module - send and receive SMS; MSN module; Windows Live Messenger chat Book Reader - reading books by speech synthesis; and Web Browsing - special plug-ins for Bing Maps and Facebook.
The developers of the software and hardware will continue to work with HealthMed on an outsourcing basis in developing further applications for the Neural Communicator.
President/CFO John Popovic commented, "We are extremely keen on completing the acquisition of Neural Communicator. The product will bring easy communication capability to those currently unable to communicate as well as expanding the communication ability of others with disabilities restricting their communication capacity. Acquiring this leading edge technology expands HealthMed's product lineup and will position us strongly in the marketplace."
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact: John Popovic
www.healthmedltd.com866.428.5689
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Healthcare Technology Stocks; HealthMed Services (OTC.BB:HEME) to Acquire Neural Communicator
Investorideas.com - Healthcare Technology Stocks; HealthMed Services (OTC.BB:HEME) to Acquire Neural Communicator
Category: Investment, Health Care
Visit this company: www.healthmedltd.com
SUNNYVALE, CA - September 2, 2010 (Investorideas.com Newswire) – HealthMed Services Ltd. (OTC.BB:HEME), an innovative software development company, is pleased to announce that it has entered final negotiations to acquire all rights, title and interest to Neural Communicator software and hardware.
Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. The device detects eye movement, jaw contractions and ALPHA and BETA brain waves allowing hands free input.
Neural Communicator is intended for people disabled in such a way that they cannot communicate by speech or by using their body. Biofeedback is used for computer input and controlling the application features.
The software is based on plug-in architecture allowing easy implementation of new features. There are five basic modules:
Speech module - text input for speech replacement; GSM module - send and receive SMS; MSN module; Windows Live Messenger chat Book Reader - reading books by speech synthesis; and Web Browsing - special plug-ins for Bing Maps and Facebook.
The developers of the software and hardware will continue to work with HealthMed on an outsourcing basis in developing further applications for the Neural Communicator.
President/CFO John Popovic commented, "We are extremely keen on completing the acquisition of Neural Communicator. The product will bring easy communication capability to those currently unable to communicate as well as expanding the communication ability of others with disabilities restricting their communication capacity. Acquiring this leading edge technology expands HealthMed's product lineup and will position us strongly in the marketplace."
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact:
John PopovicDirectorwww.healthmedltd.comEmail Contact866.428.5689
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Category: Investment, Health Care
Visit this company: www.healthmedltd.com
SUNNYVALE, CA - September 2, 2010 (Investorideas.com Newswire) – HealthMed Services Ltd. (OTC.BB:HEME), an innovative software development company, is pleased to announce that it has entered final negotiations to acquire all rights, title and interest to Neural Communicator software and hardware.
Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. The device detects eye movement, jaw contractions and ALPHA and BETA brain waves allowing hands free input.
Neural Communicator is intended for people disabled in such a way that they cannot communicate by speech or by using their body. Biofeedback is used for computer input and controlling the application features.
The software is based on plug-in architecture allowing easy implementation of new features. There are five basic modules:
Speech module - text input for speech replacement; GSM module - send and receive SMS; MSN module; Windows Live Messenger chat Book Reader - reading books by speech synthesis; and Web Browsing - special plug-ins for Bing Maps and Facebook.
The developers of the software and hardware will continue to work with HealthMed on an outsourcing basis in developing further applications for the Neural Communicator.
President/CFO John Popovic commented, "We are extremely keen on completing the acquisition of Neural Communicator. The product will bring easy communication capability to those currently unable to communicate as well as expanding the communication ability of others with disabilities restricting their communication capacity. Acquiring this leading edge technology expands HealthMed's product lineup and will position us strongly in the marketplace."
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact:
John PopovicDirectorwww.healthmedltd.comEmail Contact866.428.5689
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Wednesday, September 1, 2010
Investorideas.com - Biotech Stocks; UV Flu Technologies (OTCBB: UVFT) UV-400 Generating Excitement in the Air Purifier Marketplace
Investorideas.com - Biotech Stocks; UV Flu Technologies (OTCBB: UVFT) UV-400 Generating Excitement in the Air Purifier Marketplace
Persistent Odor and VOC Reduction Capability Gets Favorable Response
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
CENTERVILLE, MA - September 1, 2010 (Investorideas.com Newswire) – UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that the improved features added to its UV-400 air purifier have been generating a surprising amount of interest from distributors.
The Company recently began coating the inside of its patented UV-400 cartridge with a thin layer of the photo-catalyst Titanium Dioxide (TiO2). Combined with the germicidal UV lamps contained within the cartridge, and moisture in the air, the hydroxyl radicals produced by the TiO2 accelerate the breakdown of molecular bonds present as odors or in the case of Volatile Organic Compounds ("VOC"). These compounds are converted into harmless water vapor and carbon dioxide, which results in significantly reducing the concentration and effects of odors and VOC's.
"Volatile Organic Compounds, such as acetone, formaldehyde, benzene, as well as hundreds of other compounds, are surprisingly common in offices or households, and can be harmful in even small concentrations to people with respiratory problems, especially children and the elderly," stated Jack Lennon, President of UV Flu Technologies. "Carpets, building materials, cleaning supplies, paints and varnishes, vinyl floors and furniture, air fresheners, copiers and printers, pesticides, secondhand smoke, wood burning stoves, nail polish remover and hair products; are all just a small sample of the products emitting VOC's, many of which cause allergic reactions, as well as many of them containing known carcinogens. The UV-400 product has undergone laboratory tests which show the concentration of VOC's are reduced significantly with each pass, which is repeated several times per hour in a typical room."
"Many of our customers are very excited about this feature," commented Bill Fegley, President of Puravair, a major distributor of UV Flu products. "The reduction of the concentration of these compounds and odors is considered very important to a wide array of our customer base, such as salons, health clubs, funeral homes, restaurants and athletic facilities. This feature, combined with the UV-400's proven ability to kill bacteria, make it a compelling purchase for any location that commonly finds these types of airborne contaminants present in the course of their day-to-day operations."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Persistent Odor and VOC Reduction Capability Gets Favorable Response
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
CENTERVILLE, MA - September 1, 2010 (Investorideas.com Newswire) – UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that the improved features added to its UV-400 air purifier have been generating a surprising amount of interest from distributors.
The Company recently began coating the inside of its patented UV-400 cartridge with a thin layer of the photo-catalyst Titanium Dioxide (TiO2). Combined with the germicidal UV lamps contained within the cartridge, and moisture in the air, the hydroxyl radicals produced by the TiO2 accelerate the breakdown of molecular bonds present as odors or in the case of Volatile Organic Compounds ("VOC"). These compounds are converted into harmless water vapor and carbon dioxide, which results in significantly reducing the concentration and effects of odors and VOC's.
"Volatile Organic Compounds, such as acetone, formaldehyde, benzene, as well as hundreds of other compounds, are surprisingly common in offices or households, and can be harmful in even small concentrations to people with respiratory problems, especially children and the elderly," stated Jack Lennon, President of UV Flu Technologies. "Carpets, building materials, cleaning supplies, paints and varnishes, vinyl floors and furniture, air fresheners, copiers and printers, pesticides, secondhand smoke, wood burning stoves, nail polish remover and hair products; are all just a small sample of the products emitting VOC's, many of which cause allergic reactions, as well as many of them containing known carcinogens. The UV-400 product has undergone laboratory tests which show the concentration of VOC's are reduced significantly with each pass, which is repeated several times per hour in a typical room."
"Many of our customers are very excited about this feature," commented Bill Fegley, President of Puravair, a major distributor of UV Flu products. "The reduction of the concentration of these compounds and odors is considered very important to a wide array of our customer base, such as salons, health clubs, funeral homes, restaurants and athletic facilities. This feature, combined with the UV-400's proven ability to kill bacteria, make it a compelling purchase for any location that commonly finds these types of airborne contaminants present in the course of their day-to-day operations."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Tuesday, August 24, 2010
Investorideas.com - BioSante Pharmaceuticals (NASDAQ: BPAX) Company Profile at Investorideas.com
Investorideas.com - BioSante Pharmaceuticals (NASDAQ: BPAX) Company Profile at Investorideas.com
BioSante is focused on developing innovative products for female sexual health and oncology
Subscribe to Investor Ideas Newswire
Visit this company: www.biosantepharma.com
August 24, 2010 - (Investorideas.com newswire) www.InvestorIdeas.com, an investor research portal covering multiple sectors including biotech stocks and pharma stocks, announces the new company profile for pharma stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for interested investors.
BioSante (NASDAQ: BPAX ) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Visit BioSante’s profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/ or visit the BioSante website at www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech/Pharma Stocks portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.Visit the Biotech stocks Directory
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was brought to Investorideas.com by Money Channel TV http://www.moneychannel.tv/. The Money Channel’s "Steve Crowley's American Scene" was launched from the Disney/MGM Radio Studios at the Walt Disney World Resort in June 1990. The American Scene has millions of listeners on its three-hour daily radio broadcasts through the mighty IRN/USA Radio Network affiliates, plus other affiliates. There also is a growing listening audience on the Internet worldwide. In addition in The Money Channel produces WallStreetCast, a half hour program airing on FOX Business. WallStreetCast has highlighted some of today’s top experts and advisors from Wall Street and some of the best public companies in the market. Steve Crowley interviews top experts, analysts, money managers and authors covering stocks, investments, business, the economy and trends, Small-Cap CEOs and much more. More than 200 Financial “Stars” are interviewed in constant rotation….from Steve Forbes, Tobin Smith, Beth Dater, Joe Battipaglia, Larry Kudlow plus many more.
Disclaimer: The BioSante Pharmaceuticals, Inc company profile is a paid for submission profile. Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.aspDisclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For information about BioSante Pharmaceuticals, Inc.Contact:
The Trout Group LLCTricia Swanson(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com
BioSante is focused on developing innovative products for female sexual health and oncology
Subscribe to Investor Ideas Newswire
Visit this company: www.biosantepharma.com
August 24, 2010 - (Investorideas.com newswire) www.InvestorIdeas.com, an investor research portal covering multiple sectors including biotech stocks and pharma stocks, announces the new company profile for pharma stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for interested investors.
BioSante (NASDAQ: BPAX ) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Visit BioSante’s profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/ or visit the BioSante website at www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech/Pharma Stocks portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.Visit the Biotech stocks Directory
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was brought to Investorideas.com by Money Channel TV http://www.moneychannel.tv/. The Money Channel’s "Steve Crowley's American Scene" was launched from the Disney/MGM Radio Studios at the Walt Disney World Resort in June 1990. The American Scene has millions of listeners on its three-hour daily radio broadcasts through the mighty IRN/USA Radio Network affiliates, plus other affiliates. There also is a growing listening audience on the Internet worldwide. In addition in The Money Channel produces WallStreetCast, a half hour program airing on FOX Business. WallStreetCast has highlighted some of today’s top experts and advisors from Wall Street and some of the best public companies in the market. Steve Crowley interviews top experts, analysts, money managers and authors covering stocks, investments, business, the economy and trends, Small-Cap CEOs and much more. More than 200 Financial “Stars” are interviewed in constant rotation….from Steve Forbes, Tobin Smith, Beth Dater, Joe Battipaglia, Larry Kudlow plus many more.
Disclaimer: The BioSante Pharmaceuticals, Inc company profile is a paid for submission profile. Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.aspDisclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For information about BioSante Pharmaceuticals, Inc.Contact:
The Trout Group LLCTricia Swanson(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com
Subscribe to:
Posts (Atom)